Announcements Trials

Browse Landscape

Status

Sponsor Class

Study Type

Expanded_access 1

Sponsor

Cancer Type

Tumor-Agnostic 1

Conditions

Sarcoma 3 Wilms Tumor 2 Sarcoma, Ewing 2 Rhabdomyosarcoma 2 Rhabdoid Tumor 2 Osteosarcoma 2 Neuroectodermal Tumors, Primitive, Peripheral 2 Neuroblastoma 2 Medulloblastoma 2 Lymphoma, Non-Hodgkin 2 Histiocytosis, Langerhans-Cell 2 Hepatoblastoma 2 Glioma 2 Ependymoma 2 Central Nervous System Neoplasms 2 Breast Neoplasms 2 Xanthogranuloma, Juvenile 1 Ovarian Neoplasms 1 Neoplasms 1 Histiocytic Sarcoma 1 Endometrial Neoplasms 1 Colonic Neoplasms 1 Cholangiocarcinoma 1

Interventions

pembrolizumab 91 Blood Specimen Collection 44 Cyclophosphamide 37 Nivolumab 36 Bevacizumab 36 Standard of Care 32 Carboplatin 31 Surveys and Questionnaires 29 Paclitaxel 28 atezolizumab 25 Exercise 25 Pemetrexed 24 Gemcitabine 24 Cisplatin 23 Fluorouracil 22 Radiotherapy 20 Leucovorin 20 Dexamethasone 20 Oxaliplatin 19 Docetaxel 19 Rituximab 16 Irinotecan 16 Cetuximab 16 dostarlimab 15 Drug Therapy 15 Doxorubicin 15 Biopsy 15 130-nm albumin-bound paclitaxel 15 Prednisone 14 Ipilimumab 14

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Neoplasms × LY3023414 × 1 year × Clear all

NCT02632994 2025-09-29

Master Rollover Protocol for Continued Safety Assessment of Study Drug

Eli Lilly and Company

Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡